Healthy volunteers help track new lymphoma Drug's path through the body
Knowledge-focused
Not yet recruiting
This early-stage study gives a single dose of a radioactive-labeled drug, DZD8586, to 6 healthy men aged 18-45. The goal is to see how the body absorbs, breaks down, and gets rid of the drug. Results will help design future studies for people with non-Hodgkin lymphoma.
Phase: PHASE1 • Sponsor: Dizal Pharmaceuticals • Aim: Knowledge-focused
Last updated May 11, 2026 20:38 UTC